Offers moderate repurposing potential for Parkinson's by highlighting neuroprotective and symptomatic mechanisms, but the lack of PD‑specific data, absent abstract, and limited coverage of key PD pathways (alpha‑synuclein, mitochondria, lysosomes) reduce its immediate translational value.

The compound's reported anti-inflammatory and antioxidant profiles could be relevant to PD-related pathways (mitochondria, neuroinflammation, proteostasis), making it a candidate for follow-up assays, yet the current article offers low immediate actionability for Parkinson’s therapeutic discovery.

Better CT-guided normalization can improve accuracy and reproducibility of DAT SPECT biomarkers for diagnosis, patient stratification, and monitoring in Parkinson's therapeutic trials, though it does not provide direct mechanistic or interventional insights.

While not offering molecular or therapeutic targets, the paper identifies candidate biomechanical biomarkers and measurement gaps that could inform clinical phenotyping, outcome measures, and rehabilitation strategies relevant to Parkinson's gait dysfunction and trial design.

Brain-age prediction methods can provide noninvasive biomarkers for early diagnosis, disease monitoring, and trial stratification in PD, improving translational research and clinical evaluation despite not directly revealing therapeutic mechanisms.

By linking metabolic/inflammatory mechanisms (and potential repurposing of diabetes drugs) to neurodegeneration, the paper could guide translational strategies for PD, but its narrative format and missing abstract reduce immediate actionability.

By concentrating on peripheral immune pathways and their communication with the CNS (including inflammation and potential gut–brain interactions), it may point to biomarkers and immune-modulating therapeutic strategies, though the missing abstract limits assessment of novelty and actionability.

These genes point to lysosomal dysfunction, a therapeutically actionable pathway and biomarker axis relevant to GBA-related and broader PD biology, but being a correction with no abstract or new experimental data limits immediate translational impact until the original findings are reviewed.

Clinically relevant for optimizing levodopa delivery and reducing motor fluctuations (high translational value), but offers limited mechanistic or disease‑modifying insight and evaluation is constrained by the missing abstract.

Findings are clinically actionable because reduced levodopa-induced homocysteine via COMT inhibition could lower vascular and potential neurotoxic risk and guide adjunct strategies (COMT inhibitor choice or B‑vitamin management) to improve long-term outcomes, though lack of an abstract limits…

Highlights the gut–brain axis and microbiome as promising, translational targets for PD diagnostics and interventions, but absence of an abstract and likely review nature limit immediate actionable insights.

If levodopa contributes to neuropathy via metabolic changes (e.g., B12/homocysteine pathways), the finding could guide monitoring, simple supplementation or management strategies to improve safety and tolerability of a cornerstone therapy, though it is less directly informative about core…

If supported by experimental data, this gut-immune—ENS connection could yield biomarkers or therapeutic entry points to modulate inflammation or block pathology spread, but the missing abstract limits assessment of actionable evidence and translational readiness.

Macrophage-focused research intersects with inflammation, alpha-synuclein clearance, and peripheral biomarkers—areas with translational and therapeutic potential—yet the missing abstract and likely speculative review format limit immediate actionability for drug discovery.

Connects metabolism, homocysteine and methylation to neurodegeneration and highlights biomarker and repurposing opportunities (e.g., folate supplementation), but is non‑specific to Parkinson's and lacks clear, actionable therapeutic targets or novel PD‑focused data.

Provides clinically actionable repurposing evidence for managing perioperative depression in PD—relevant for symptom control and perioperative outcomes—but offers limited insight into disease‑modifying mechanisms or core PD biology.

Microbiome modulation is a plausible, translationally relevant avenue for PD (gut–brain interactions, inflammation, metabolism), but the lack of accessible data or mechanistic/clinical detail limits immediate utility for therapeutic discovery.

Highlights a potentially useful non‑pharmacological, translational avenue for symptom management and improved phenotyping of gait disturbances, but offers limited actionable insights for drug discovery or molecular target development.

Improving discrimination of true beta-burst signals could refine electrophysiological biomarkers and DBS tuning with translational relevance, but absence of an abstract and limited mechanistic or therapeutic content reduce its direct value for drug discovery.

Improved interpretable prediction could help identify candidate biomarkers and stratify patients for trials, but with no abstract and little mechanistic or therapeutic content the paper has limited direct value for drug discovery.

May inform biomarker-based differentiation between PD and tremor disorders and improve early diagnosis, but offers limited direct mechanistic or therapeutic insights for Parkinson's drug discovery.

Although it does not address molecular mechanisms or drug targets, the paper has translational clinical value by informing personalized DBS targeting and predictive modeling to reduce cognitive side effects, which can improve patient outcomes and trial design for neuromodulation interventions.

Relevant to symptomatic management and to understanding autonomic involvement in PD (which could inform biomarkers or peripheral alpha‑synuclein pathology), but with limited immediate value for novel therapeutic discovery given the likely clinical/symptom focus and lack of available abstract.

Cerebral perfusion could reveal vascular contributions, imaging biomarkers, or repurposable vascular interventions for PD, but the editorial format and missing abstract limit immediate actionable or translational value.

It flags epidemiological links between diet and PD that could motivate mechanistic work on gut-brain and metabolic pathways, but as a comment it offers limited actionable insights for therapy development.